<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747110</url>
  </required_header>
  <id_info>
    <org_study_id>BUC-57/UCA</org_study_id>
    <secondary_id>2006-005377-22</secondary_id>
    <nct_id>NCT00747110</nct_id>
  </id_info>
  <brief_title>Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)</brief_title>
  <official_title>Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9
      mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative
      colitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission (defined by CAI &lt;= 4, with stool frequency and rectal bleeding subscores of ´0´) at week 8 (LOCF)</measure>
    <time_frame>week 8 (LOCF)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first resolution of clinical symptoms</measure>
    <time_frame>within 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAI in the course of the study</measure>
    <time_frame>week 0, 2, 4, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Index (DAI)in the course of the study</measure>
    <time_frame>week 0 and 8 (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopical Index (EI)in the course of the study</measure>
    <time_frame>week 0 and 8 (LOCF)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">343</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9mg budesonide OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3g mesalazine OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>3x 3mg budesonide capsules once daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Budenofalk 3mg capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalazine</intervention_name>
    <description>3x 1000mg mesalazine onc daily</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Salofalk 1000mg granules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent,

          2. Men or women aged 18 to 75 years,

          3. Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by
             endoscopy and histology,

          4. Established disease (presence of blood or mucus in the stools) or new diagnosis
             (bloody stools occurring at least during 14 days prior to baseline visit),

          5. Clinical Activity Index (CAI) &gt;= 6 and Endoscopical Index (EI) &gt;= 4,

          6. Women of child-bearing potential, if heterosexually active, have to apply a highly
             effective method of birth control, which is defined as those which result in a low
             failure rate (i.e., less than 1% per year) when used consistently and correctly such
             as implants, injectables, combined oral contraceptive method, some intrauterine
             devices (IUDs), sexual abstinence, or vasectomised partner. The investigator is
             responsible for determining whether the subject has adequate birth control for study
             participation.

        Exclusion Criteria:

          1. Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis,
             microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),

          2. Toxic megacolon,

          3. Baseline stool positive for germs causing bowel disease,

          4. Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the
             gastrointestinal tract,

          5. Active peptic ulcer disease,

          6. Haemorrhagic diathesis,

          7. Asthma, diabetes mellitus, infection, osteoporosis, glaucoma, cataract, or
             cardiovascular disease if careful medical monitoring is not ensured,

          8. Severe co-morbidity substantially reducing life expectancy,

          9. Active colorectal cancer or a history of colorectal cancer,

         10. Active malignancy other than colorectal cancer or treatment with anticancer drugs
             during the last 5 years. Patients with a history of cancer other than colorectal
             cancer and at least five years of uneventful follow up and no signs of recurrence may
             be eligible,

         11. Immunosuppressants within 3 months and/or corticosteroids (oral, intravenous [IV] or
             topical rectal) within 4 weeks prior to baseline,

         12. Current relapse occurred under maintenance treatment with &gt; 2.4 g mesalazine per day,

         13. Abnormal renal function (Serum Cystatin C &gt; upper limit of normal [ULN]),

         14. Abnormal hepatic function (ALT, AST or AP &gt;= 2 x ULN) or liver cirrhosis,

         15. Known intolerance/hypersensitivity/resistance to study drugs or drugs of similar
             chemical structure or pharmacological profile, or to any of the other constituents of
             the study drugs,

         16. Doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs,

         17. Existing or intended pregnancy or breast-feeding,

         18. Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Mueller, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R; International BUC-57 Study Group. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2011 Apr;5(2):129-38. doi: 10.1016/j.crohns.2010.11.006. Epub 2010 Dec 14.</citation>
    <PMID>21453882</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>5-ASA</keyword>
  <keyword>mesalamine</keyword>
  <keyword>mesalazine</keyword>
  <keyword>budesonide</keyword>
  <keyword>ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

